[3]
Buckner JC, Brown PD, O’Neill BP, et al. Central nervous system tumors. Mayo Clin Proc 2007; 82(10): 1271-86.
[5]
Kleihues P, Cavenee WK, Eds. WHO Classification of tumors: Pathology and genetics of tumors of the nervous system. : IARC Press Germany 2000.
[6]
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20: 22-39.
[7]
Walcott BP, Nahed BV, Brastianos PK, et al. Radiation Treatment for WHO Grade II and III Meningiomas. Front Oncol 2013; 3: 227.
[8]
Fowd CF, Halback VV, Higashida RT. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 2003; 15: 1-4.
[9]
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
[10]
Bindal RK, Sawaya R, Leavens ME, et al. Surgical treatment of multiple brain metastases. J Neurosurg 1993; 79(2): 210-6.
[11]
Ohgaki H, Kleihues P. Genetic Pathways to Primary and Secondary Glioblastoma. Am J Pathol 2007; 170(5): 1445-53.
[12]
Verhaak RG, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 2010; 17(1): 98.
[13]
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003.
[14]
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
[15]
Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma: prognosis, extent of resection, and survival. J Neurosurg 2001; 95(2): 190-8.
[16]
Freije WA, Castro-Vargas E, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004; 64: 6503-10.
[17]
Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
[18]
The Cancer Genome Altas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372: 2481-98.
[19]
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803-20.
[20]
Macaulay RJ. Impending impact of molecular pathology on classifying adult diffuse gliomas. Cancer Control 215; 22(2): 200-5..
[21]
Aghi MK, Nahed BV, Sloan AE, et al. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2015; 125(3): 503-30.
[22]
Nimsky C, Ganslandt O, Hastreiter P, et al. Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery 2005; 56(1): 130-7.
[23]
De Benedictis A, Moritz-Gasser S, Duffau H. Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery 2010; 66(6): 1074-84.
[24]
Hervey-Jumper SL, Berger MS. Maximizing safe resection of low and high-grade glioma. J Neurooncol 2016; 130(2): 269-82.
[25]
Barbosa BJ, Mariano ED, Batista CM, et al. Intraoperative assistive technologies and extent of resection in glioma surgery: A systematic review of prospective controlled studies. Neurosurg Rev 2015; 38(2): 217-27.
[26]
Carrabba G, Fava E, Guissani C, et al. Cortical and subcortical motor mapping in rolandic and perirolanddic glioma surgery: Impact on postoperative morbidity and extent of resection. J Neurosurg Sci 2007; 51(2): 45-51.
[28]
Fenchel M, Beschorner R, Naegele T, et al. Primarily solid intraventricular brain tumors. Eur J Rad 2012; 81: e688-96.
[29]
Pan DH, Lee CC. The management of incidental central neurocytoma. Neurosurg Clin N Am 2015; 26: 57-66.
[30]
Rhoton A. Cranial anatomy and surgical approaches. In: Congress of Neurological Surgeons. Oxford University Press UK 2003.
[31]
Thomas AG, Koumellis P, Dineen RA. The fornix in health and disease: an imaging review. Radiographics 2011; 31: 1107-21.
[32]
Schroeder H. Intraventricular tumors World Neurosurg 2013; 79(25): s17.e15-s17.e19.
[33]
Pettorini BL, Frassanito P, Caldarelli M, et al. Molecular pathogenesis of craniopharyngioma: switching from a surgical approach to a biological one. Neurosurg Focus 2010; 28(4)E1
[34]
Lopez-Serna R, Gomez-Amador JL, Barges-Coll J, et al. Treatment of craniopharyngioma in adults: Systematic analysis of a 25-year experience. Arch Med Res 2012; 43: 347-55.
[35]
Zada GZ, Lin N, Ojerholm E, et al. Craniopharyngioma and other cystic epithelial lesions of the sellar region: A review of clinical, imaging and histopathological relationships. Neurosurg Focus 2010; 28(4)E4
[36]
Lopez-Serna R, Gomez-Amador JL, Barges-Coll J, et al. Treatment of craniopharyngioma in adults: systematic analysis of a 25-year experience. Arch Med Res 2012; 43: 347-55.
[37]
Yang I, Sughrue ME, Rutkowski MJ, et al. Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 2010; 28(4)E5
[38]
Mortini P, Gagliardi F, Boari N, et al. Surgical strategies and modern therapeutic options in the treatment of cranio-pharyngiomas. Crit Rev Onc Hem 2013; 88: 514-29.
[39]
Buchfelder M, Schlaffer SM, Lin F, et al. Surgery for craniopharyngioma. Pituitary 2013; 16: 18-25.
[40]
Bresson D, Herman P, Polivka M, et al. Sellar lesions/pathology. Otolaryngol Clin N Am 2016; 49: 63-93.
[41]
Farrell CJ, Nyquist GG, Farag AA, et al. Principles of Pituitary Surgery. Otolaryngol Clin N Am 2016; 49: 95-106.
[42]
Sonabend AM, Bowden S, Bruce JN. Microsurgical resection of pineal tumors. J Neurooncol 2016; 130(2): 351-66.
[43]
Choudhri AF, Siddiqui A, Klimo P. Pediatric cerebellar tumors: emerging imaging techniques and advances in understanding genetic features. Neuroimag Clin N Am 2016; 26: 459-69.
[44]
Coluccia D, Figuereido C, Isik S, et al. Medulloblastoma: Tumor biology and relevance to treatment and prognosis paradigm. Curr Neurol Neurosci Rep 2016; 2016: 43.
[45]
Shih RY, Smirniotopoulos JG. Posterior fossa tumors in adult patients. Neuroimag Clin N Am 2016; 26: 493-510.
[46]
Carlson ML, Link MJ, Wanna GB, et al. Management of sporadic vestibular schwannoma. Otolaryngol Clin N Am 2015; 48: 407-22.
[47]
Joaquim AF, Powers A, Laufer I, et al. An update in the management of spinal metastases. Arq Neuropsiquiatr 2015; 73(9): 795-802.
[48]
Feiz-Erfan I, Rhines LD, Weinberg JS. The role of surgery in the management of metastatic spine tumors. Sem Onc 2008; 35(2): 108-17.
[49]
Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol 2008; 7: 459-66.
[50]
Samartzis D, Gillis CC, Shih P, et al. Intramedullary spinal cord tumors: part I – epidemiology, pathophysiology and diagnosis. Global Spine J 2015; 5: 425-35.
[51]
Samartzis D, Gillis CC, Shih P, et al. Intramedullary spinal cord tumors: Part II – management options and outcomes. Global Spine J 2016; 6: 176-85.
[52]
Barrese JC, Henderson JM. Image-guided surgery. Current Problems in Surgery 2015; 52: 476-520.
[53]
Paldor I, Drummond KJ, Awad M, et al. Is a wake-up call in order? Review of the evidence for awake craniotomy. J Clin Neurosci 2016; 23: 1-7.
[54]
Hervey-Jumper SL, Berger MS. Technical nuances of awake brain tumor surgery and the role of maximum safe resection. J Neurosurg Sci 2015; 59: 351-60.
